Viloxazine: A New Non-Stimulant Treatment for Attention-Deficit/Hyperactivity Disorder (ADHD)

Viloxazine: A New Non-Stimulant Treatment for Attention-Deficit/Hyperactivity Disorder (ADHD)

Introduction Viloxazine is an antidepressant medication classified as an SNRI (serotonin and norepinephrine reuptake inhibitor). In April 2021, it received FDA approval in the United States for the treatment of ADHD in children aged 6 to 17. Subsequently, in May 2022, it was also approved for the tr...

Full description

Saved in:
Bibliographic Details
Main Authors: Wiktoria (Author), Anna Greguła (Author), Karol Stachyrak (Author), Dawid Mika (Author), Aleksandra Kłos (Author), Kamila Turek (Author), Maciej Lambach (Author), Mateusz Pawlicki (Author), Aleksandra Mazurek (Author), Bartosz Mazur (Author)
Format: Book
Published: Kazimierz Wielki University, 2024-02-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items